RxDoctor Payments Data

Shivendra Bansal, MD

Family Medicine · Shawnee, OKNPI 1144679952

Payments from drug & device makers

$788in general payments, 2019–2025

Across 36 payments — averaging $21.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$257
  • AbbVie$210
  • Novo Nordisk$197
  • Lilly USA, LLC$37
  • Astellas Pharma US Inc$25
  • Dexcom, Inc.$22
  • plus $40 from 2 others

What the payments were for

  • Food & beverage$788100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca12$257
AbbVie(2 entities)5$210
Novo Nordisk13$197
Lilly USA, LLC2$37
Astellas Pharma US Inc1$25
Dexcom, Inc.1$22
Exact Sciences1$21
Pfizer1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$788 in reported general payments places this provider in the 60th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$82,560
Medicare patients
277
Services billed
1,179

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide145$241,805
JardianceEmpagliflozin46$65,195
Trelegy ElliptaFluticasone/Umeclidin/Vilanter96$64,456
EliquisApixaban57$60,573
TrulicityDulaglutide33$57,756
RybelsusSemaglutide13$30,788
MounjaroTirzepatide13$22,306
XareltoRivaroxaban21$18,484
JanuviaSitagliptin Phosphate12$18,455
MyrbetriqMirabegron13$17,075
EntrestoSacubitril/Valsartan16$14,839
Buprenorphine46$10,781
Breo ElliptaFluticasone/Vilanterol24$9,511
BelbucaBuprenorphine Hcl14$9,367
GemtesaVibegron13$8,356

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$197$272,593158 claims
Lilly USA, LLCTrulicity, Mounjaro$37$80,06146 claims
PfizerEliquis$18$60,57357 claims
Astellas Pharma US IncMyrbetriq$25$17,07513 claims
AstraZenecaBreztri Aerosphere$257$8,28911 claims
AbbVieSynthroid$210$2,39537 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Shawnee

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →